c反应蛋白/血小板比率作为异基因造血干细胞移植前的生物标志物对恶性淋巴瘤的预后价值

IF 3.9 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-09-08 DOI:10.1002/hon.70136

Akihiko Izumi, Takayoshi Tachibana, Hiroto Ishii, Shin-ichiro Fujiwara, Yuho Najima, Chikako Ohwada, Kota Yoshifuji, Yuto Hibino, Masatsugu Tanaka, Shinichi Kako, Shun-ichi Kimura, Masaharu Tamaki, Shingo Yano, Hiroki Yokoyama, Daisuke Minakata, Shokichi Tsukamoto, Emiko Sakaida, Noriko Doki, Akira Yokota, Takuya Miyazaki, Nobuyuki Aotsuka, Yoshinobu Kanda

{"title":"c反应蛋白/血小板比率作为异基因造血干细胞移植前的生物标志物对恶性淋巴瘤的预后价值","authors":"Akihiko Izumi, Takayoshi Tachibana, Hiroto Ishii, Shin-ichiro Fujiwara, Yuho Najima, Chikako Ohwada, Kota Yoshifuji, Yuto Hibino, Masatsugu Tanaka, Shinichi Kako, Shun-ichi Kimura, Masaharu Tamaki, Shingo Yano, Hiroki Yokoyama, Daisuke Minakata, Shokichi Tsukamoto, Emiko Sakaida, Noriko Doki, Akira Yokota, Takuya Miyazaki, Nobuyuki Aotsuka, Yoshinobu Kanda","doi":"10.1002/hon.70136","DOIUrl":null,"url":null,"abstract":"<div>\n \n Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021. CP ratio was defined as CRP [mg/dL]/platelet [104/μL] and evaluated prior to alloHCT. The cutoff value for CP ratio was set at 0.05 based on previous studies. A total of 311 cases were analyzed, of which 134 were mature B cell lymphoma, 177 were T/NK cell lymphoma (including 70 cases of adult T-cell leukemia/lymphoma), and 17 were Hodgkin's lymphoma. The median age was 53 years (range: 17–69 years). High CP ratio was associated with status of disease, presence of infections, poor performance status at alloHCT, and high transfusion volume received prior to alloHCT. Overall survival (OS) at 2 years according to CP ratio (low vs. high) was 61.1% versus 30.1% (p < 0.001), non-relapse mortality (NRM) was 21.4% versus 40.7% (p = 0.001), and the relapse rate was 23.7% versus 32.6% (p = 0.061), respectively. In multivariate analysis, the high CP ratio group was associated with poor OS (HR = 2.20, 95% CI: 1.61–3.02, p < 0.001) and higher NRM (HR = 1.90, 95% CI: 1.28–2.81, p = 0.0014). High CP ratio was found to be associated with poor post-transplant OS and NRM, and was a suitable prognostic biomarker for stratifying the risk of patients with ML who are candidates for alloHCT.\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 5","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Value of C-Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma\",\"authors\":\"Akihiko Izumi, Takayoshi Tachibana, Hiroto Ishii, Shin-ichiro Fujiwara, Yuho Najima, Chikako Ohwada, Kota Yoshifuji, Yuto Hibino, Masatsugu Tanaka, Shinichi Kako, Shun-ichi Kimura, Masaharu Tamaki, Shingo Yano, Hiroki Yokoyama, Daisuke Minakata, Shokichi Tsukamoto, Emiko Sakaida, Noriko Doki, Akira Yokota, Takuya Miyazaki, Nobuyuki Aotsuka, Yoshinobu Kanda\",\"doi\":\"10.1002/hon.70136\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021. CP ratio was defined as CRP [mg/dL]/platelet [104/μL] and evaluated prior to alloHCT. The cutoff value for CP ratio was set at 0.05 based on previous studies. A total of 311 cases were analyzed, of which 134 were mature B cell lymphoma, 177 were T/NK cell lymphoma (including 70 cases of adult T-cell leukemia/lymphoma), and 17 were Hodgkin's lymphoma. The median age was 53 years (range: 17–69 years). High CP ratio was associated with status of disease, presence of infections, poor performance status at alloHCT, and high transfusion volume received prior to alloHCT. Overall survival (OS) at 2 years according to CP ratio (low vs. high) was 61.1% versus 30.1% (p < 0.001), non-relapse mortality (NRM) was 21.4% versus 40.7% (p = 0.001), and the relapse rate was 23.7% versus 32.6% (p = 0.061), respectively. In multivariate analysis, the high CP ratio group was associated with poor OS (HR = 2.20, 95% CI: 1.61–3.02, p < 0.001) and higher NRM (HR = 1.90, 95% CI: 1.28–2.81, p = 0.0014). High CP ratio was found to be associated with poor post-transplant OS and NRM, and was a suitable prognostic biomarker for stratifying the risk of patients with ML who are candidates for alloHCT.\\n </div>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 5\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70136\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70136","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

先前的研究表明，移植前c反应蛋白(CRP)/血小板比率（CP比率）是存活的一个预测指标。本多中心回顾性研究的目的是评估CP比值在恶性淋巴瘤（ML）患者接受同种异体造血干细胞移植（alloHCT）中的临床意义。该队列包括2007年至2021年首次接受同种异体ct治疗的ML患者。CP比值定义为CRP [mg/dL]/血小板[104/μL]，并在同种异体hct前评估。参照以往研究，CP比临界值设为0.05。共分析311例，其中成熟B细胞淋巴瘤134例，T/NK细胞淋巴瘤177例（其中成人T细胞白血病/淋巴瘤70例），霍奇金淋巴瘤17例。中位年龄为53岁（范围：17-69岁）。高CP比与疾病状态、感染存在、异体hct表现不佳以及异体hct前接受的高输血量有关。根据CP比（低vs高），2年总生存率（OS）分别为61.1% vs 30.1% (p < 0.001)，非复发死亡率（NRM）分别为21.4% vs 40.7% (p = 0.001)，复发率分别为23.7% vs 32.6% （p = 0.061）。在多因素分析中，高CP比组与较差的OS （HR = 2.20, 95% CI: 1.61-3.02, p < 0.001）和较高的NRM （HR = 1.90, 95% CI: 1.28-2.81, p = 0.0014）相关。研究发现，高CP比率与移植后不良的OS和NRM相关，是区分同种异体hct候选ML患者风险的合适预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognostic Value of C-Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma

Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021. CP ratio was defined as CRP [mg/dL]/platelet [10^4/μL] and evaluated prior to alloHCT. The cutoff value for CP ratio was set at 0.05 based on previous studies. A total of 311 cases were analyzed, of which 134 were mature B cell lymphoma, 177 were T/NK cell lymphoma (including 70 cases of adult T-cell leukemia/lymphoma), and 17 were Hodgkin's lymphoma. The median age was 53 years (range: 17–69 years). High CP ratio was associated with status of disease, presence of infections, poor performance status at alloHCT, and high transfusion volume received prior to alloHCT. Overall survival (OS) at 2 years according to CP ratio (low vs. high) was 61.1% versus 30.1% (p < 0.001), non-relapse mortality (NRM) was 21.4% versus 40.7% (p = 0.001), and the relapse rate was 23.7% versus 32.6% (p = 0.061), respectively. In multivariate analysis, the high CP ratio group was associated with poor OS (HR = 2.20, 95% CI: 1.61–3.02, p < 0.001) and higher NRM (HR = 1.90, 95% CI: 1.28–2.81, p = 0.0014). High CP ratio was found to be associated with poor post-transplant OS and NRM, and was a suitable prognostic biomarker for stratifying the risk of patients with ML who are candidates for alloHCT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.